Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Alderman M. H., Madhavan S., Ooi W. L., Cohen H., Sealey J. E., Laragh J. H. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med. 1991 Apr 18;324(16):1098–1104. doi: 10.1056/NEJM199104183241605. [DOI] [PubMed] [Google Scholar]
- Bayliss J., Norell M., Canepa-Anson R., Sutton G., Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J. 1987 Jan;57(1):17–22. doi: 10.1136/hrt.57.1.17. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Brilla C. G., Matsubara L. S., Weber K. T. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol. 1993 Jan 21;71(3):12A–16A. doi: 10.1016/0002-9149(93)90239-9. [DOI] [PubMed] [Google Scholar]
- Kendall M. J., Rajman I., Maxwell S. R. Cardioprotective therapeutics--drugs used in hypertension, hyperlipidaemia, thromboembolism, arrhythmias, the postmenopausal state and as anti-oxidants. Postgrad Med J. 1994 May;70(823):329–343. doi: 10.1136/pgmj.70.823.329. [DOI] [PMC free article] [PubMed] [Google Scholar]
- van Vliet A. A., Donker A. J., Nauta J. J., Verheugt F. W. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol. 1993 Jan 21;71(3):21A–28A. doi: 10.1016/0002-9149(93)90241-4. [DOI] [PubMed] [Google Scholar]
- van Vliet A. A., Hackeng W. H., Donker A. J., Meuwissen S. G. Efficacy of low-dose captopril in addition to furosemide and spironolactone in patients with decompensated liver disease during blunted diuresis. J Hepatol. 1992 May;15(1-2):40–47. doi: 10.1016/0168-8278(92)90009-e. [DOI] [PubMed] [Google Scholar]